Pro 2013-021 (Jianfeng Group Corporate Bond Listing Announcement)-2
Release time:
2020-08-05
(四)发行人设立、上市及股本变更情况
1、发行人的设立
尖峰集团的前身是金华市水泥厂,经金华市人民政府“金政[1988]100号”文批准由金华市水泥厂为主体于1989年8月8日组建浙江尖峰水泥集团股份有限公司,1991年经金华市人民政府以“金政发[1991]38号”文批准浙江尖峰水泥集团股份有限公司与浙江省水泥制品厂联合,联合后的集团公司更名为浙江尖峰建材集团股份有限公司,国家经济体制改革委员会1993年以“体改生[1993]2号”文批准继续进行股份制试点,1993年经浙江省计划经济委员会、浙江省经济体制改革委员会以“浙江计经企[1993]269号”文批准更名为浙江尖峰集团股份有限公司并升格为省批企业集团。尖峰集团于1993年3月19日变更登记,取得金华市工商行政管理局14728065-X号企业法人营业执照,注册资本70,544,793元,其中国家股占总股本的61.10%,法人股占总股本的18.35%,个人股占总股本的20.55%,已经浙江会计师事务所浙会验[1993]第286号《验资报告》确认到位。
2、发行人发行上市
1993年,中国证监会以“证监发审字[1993]18号”文批准尖峰集团发行的个人股股票上市流通。上交所以“上证上字[93]第2050号”文批准本公司发行的1,450万个人股股票于1993年7月28日在上交所挂牌交易,股票简称“尖峰集团”,证券代码600668。发行人股票上市时总股本为70,544,793股,其中国家股43,097,993股,占总股本的61.10%;法人股12,946,800股,占总股本的18.35%;流通A股14,500,000股,占总股本的20.55%。
3、公募法人股
根据1993年6月浙江省经济体制改革委员会《关于同意调整法人股募集比价的函复》,1993年11月浙江省经济体制改革委员会以“浙经体改[1993]20号”文批准发行人将以1:2.3的溢价比例向社会募集法人股3,580万股,实际募集法人股15,116,100股。本次募集法人股结束后,发行人总股本增加至85,660,893股,其中,非流通股国家股43,097,993股,占总股本的50.31%;非流通股法人股28,062,900股,占总股本的32.76%;流通A股14,500,000股,占总股本的16.93%。1994年3月浙江省经济体制改革委员会以“浙经体改[1994]30号”文对此次增募进行了确认。募集资金已经浙江会计师事务所浙会验[1994]第103号《验资报告》确认到位。
4、1994年送、配股
经发行人1994年4月8日第二次股东大会决议通过,并经1994年4月浙江省经济体制改革委员会浙经体改[1994]58号文及浙江省国有资产管理局[1994]国资12号文批准,发行人以总股本85,660,893股为基数,向全体股东按10:2比例送股;根据金华市财政局《关于1993年度国有股送配方案的意见》、国家股股东和法人股股东放弃配股权的书面声明,发行人将向全体流通股股东以10配15比例配股。本次送、配股完成后,发行人的总股本增加至124,543,072股,其中非流通股国家股51,717,592股,占总股本41.53%,非流通股法人股33,675,480,占总股本的27.04%,流通A股为39,150,000股,占总股本的31.43%。募集资金已经浙江会计师事务所浙会验[1994]第168号《验资报告》确认到位。
5、1995年送股
经发行人1995年4月23日1994年度股东大会决议通过,发行人以总股本124,543,072股为基数,向全体股东以10:2比例送股。本次送股后,发行人的总股本增加至149,451,686股,其中非流通国家股62,061,110股,非流通法人股40,410,576股,流通A股为46,980,000股。
6、1996年配股
经发行人1996年3月16日1995年度股东大会决议通过,并经浙江省人民政府证券委员会“浙证委[1996]5号”及中国证监会“证监发审字[1996]11号”文批准,发行人以总股本149,451,686股为基数实施每10股配2.5股。根据国家国有资产管理局国资企函发[1995]225号文及浙江省国有资产管理局[1995]77号文,国家股股东同意有偿出让国家股应配股份未认购部分15,195,265股;法人股股东同意有偿出让全部10,102,650股的配股权,社会公众股股东可按10:5.4的比例受让国家股和法人股的部分配售权。本次配股后总股本增加至186,809,330股,其中非流通国家股62,381,110股,非流通法人股40,410,576股,非流通转配股25,292,644股,流通A股为58,725,000股。募集资金已经浙江会计师事务所浙会验字[1996]第137号《验资报告》确认到位。
7、1997年送股、公积金转增股本
经发行人1997年6月6日1996年度股东大会决议通过,发行人以总股本186,809,330股为基数,向全体股东每10股送2股,同时用资本公积金每10股转增3股,送股和转增后总股本增加至280,213,995股,其中非流通国家股93,571,665股,非流通法人股60,615,864股,转配股37,938,966股;流通A股为88,087,500股。
8、1998年配股
经发行人1997年6月6日1996年度股东大会决议通过,并经浙江省证券管理委员会浙证委[1997]151号文及中国证监会“证监上字[1998]21号”文批准,发行人以总股本280,213,995股为基数,按每10股配售2股的比例实施配股。根据国家国有资产管理局国资企函发[1997]107号文和浙江省国有资产管理局[1997]28号文批复同意,国家股股东同意有偿转让国家股应配股份未认购部分11,408,933股;法人股股东同意有偿转让法人股应配股份未认购部分12,096,994股,转配股股东和社会公众股股东除可按10:2比例认购本次配售股份外,还可按10:1.865
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11